Drug or technology

Herpes Zoster Vaccine

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

JUL 30, 2026 · JOURNAL ARTICLE

Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience.

Human Vaccines & Immunotherapeutics

Single-center retrospective observational study of modest size with no control group, reporting feasibility and safety outcomes but lacking power to assess efficacy and generalizability.

PreliminaryCancer Patients Giordana Di Mauro Herpes Zoster Vaccine

Reported

Patients completing two-dose sche…37 of 42 (88.1%)

Median follow-up duration11.5 months

JUN 8, 2026 · JOURNAL ARTICLE

From awareness to action: Overcoming knowledge gaps and enhancing herpes zoster vaccination counseling among Chinese rheumatologists - Results from a nationwide survey.

Human Vaccines & Immunotherapeutics

This is a descriptive cross-sectional survey of knowledge and attitudes among Chinese rheumatologists regarding herpes zoster vaccination, with no comparator group or clinical outcome data; it identifies practice gaps and barriers but provides no evidence of intervention efficacy or clinical impact.

PreliminaryBofan Lu Herpes Zoster Vaccine Vaccines

Reported

Sample size1772

Median knowledge score (IQR)7 (6–9)

Higher regional GDP per capita co…β = 0.020, p = .040